In preclinical models of osteosarcoma, blocking TIGIT has been shown to enhance NK cell-mediated cytotoxicity, suggesting that targeting TIGIT could improve the anti-tumor immune response (56, 57). This evidence concerns the gene TIGIT and osteosarcoma.